162 related articles for article (PubMed ID: 37896829)
1. Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.
Fukao K; Nobori H; Kuroda T; Baba K; Matsumoto K; Tanaka Y; Tachibana Y; Kato T; Shishido T
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896829
[TBL] [Abstract][Full Text] [Related]
2. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
Kuroda T; Nobori H; Fukao K; Baba K; Matsumoto K; Yoshida S; Tanaka Y; Watari R; Oka R; Kasai Y; Inoue K; Kawashima S; Shimba A; Hayasaki-Kajiwara Y; Tanimura M; Zhang Q; Tachibana Y; Kato T; Shishido T
J Antimicrob Chemother; 2023 Apr; 78(4):946-952. PubMed ID: 36760083
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model.
Nobori H; Fukao K; Kuroda T; Anan N; Tashima R; Nakashima M; Noda S; Tajiri M; Torii M; Toba S; Uemura K; Sanaki T; Shishido T; Tachibana Y; Kato T
J Antimicrob Chemother; 2022 Oct; 77(11):2984-2991. PubMed ID: 35914182
[TBL] [Abstract][Full Text] [Related]
4. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Fukuhara T; Ichihashi G; Sanaki T; Baba K; Takeda Y; Tsuge Y; Uehara T
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0069722. PubMed ID: 36098519
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0063222. PubMed ID: 36094202
[TBL] [Abstract][Full Text] [Related]
7. Ensitrelvir as a potential treatment for COVID-19.
McCarthy MW
Expert Opin Pharmacother; 2022 Dec; 23(18):1995-1998. PubMed ID: 36350029
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
Yang Y; Cao L; Yan M; Zhou J; Yang S; Xu T; Huang S; Li K; Zhou Q; Li G; Zhu Y; Cong F; Zhang H; Guo D; Li Y; Zhang X
Antiviral Res; 2023 May; 213():105586. PubMed ID: 36997073
[TBL] [Abstract][Full Text] [Related]
9. A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).
Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Ichihashi G; Sanaki T; Tsuge Y; Uehara T; Mukae H
Medicine (Baltimore); 2023 Feb; 102(8):e33024. PubMed ID: 36827007
[TBL] [Abstract][Full Text] [Related]
10. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K
EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.
Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Sakaguchi H; Sonoyama T; Ichihashi G; Sanaki T; Baba K; Tsuge Y; Uehara T
Clin Infect Dis; 2023 Apr; 76(8):1403-1411. PubMed ID: 36477182
[TBL] [Abstract][Full Text] [Related]
13. S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.
Sasaki M; Tabata K; Kishimoto M; Itakura Y; Kobayashi H; Ariizumi T; Uemura K; Toba S; Kusakabe S; Maruyama Y; Iida S; Nakajima N; Suzuki T; Yoshida S; Nobori H; Sanaki T; Kato T; Shishido T; Hall WW; Orba Y; Sato A; Sawa H
Sci Transl Med; 2023 Jan; 15(679):eabq4064. PubMed ID: 36327352
[TBL] [Abstract][Full Text] [Related]
14. Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor.
Watari R; Sawada H; Hashimoto H; Kasai Y; Oka R; Shimizu R; Matsuzaki T
J Pharm Sci; 2024 Mar; 113(3):798-805. PubMed ID: 37742997
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir.
Kiso M; Yamayoshi S; Iida S; Furusawa Y; Hirata Y; Uraki R; Imai M; Suzuki T; Kawaoka Y
Nat Commun; 2023 Jul; 14(1):4231. PubMed ID: 37454219
[TBL] [Abstract][Full Text] [Related]
16. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
17. Quantum Chemical Interaction Analysis between SARS-CoV-2 Main Protease and Ensitrelvir Compared with Its Initial Screening Hit.
Watanabe C; Tanaka S; Okiyama Y; Yuki H; Ohyama T; Kamisaka K; Takaya D; Fukuzawa K; Honma T
J Phys Chem Lett; 2023 Apr; 14(15):3609-3620. PubMed ID: 37023394
[TBL] [Abstract][Full Text] [Related]
18. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir.
Jiang X; Su H; Shang W; Zhou F; Zhang Y; Zhao W; Zhang Q; Xie H; Jiang L; Nie T; Yang F; Xiong M; Huang X; Li M; Chen P; Peng S; Xiao G; Jiang H; Tang R; Zhang L; Shen J; Xu Y
Nat Commun; 2023 Oct; 14(1):6463. PubMed ID: 37833261
[TBL] [Abstract][Full Text] [Related]
19. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 3CL
Heilmann E; Costacurta F; Moghadasi SA; Ye C; Pavan M; Bassani D; Volland A; Ascher C; Weiss AKH; Bante D; Harris RS; Moro S; Rupp B; Martinez-Sobrido L; von Laer D
Sci Transl Med; 2023 Jan; 15(678):eabq7360. PubMed ID: 36194133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
